No business profile yet.
Size BellRing Brands (BRBR) is a United States Health Care company (Beverages: Non-Alcoholic) with a market value of $1.59B, the 1932nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $13.66 on 18 Nov 2026.
Performance Over six months the shares gained 52.3%, against +3.0% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth Revenue grew 3.5% over the last twelve months (peer median +15.7%); the operating margin is 10.7% (peer median -1.0%).
Valuation It trades at 10.6× forward earnings against a peer median of 17.6× (5th cheapest of 10).
Capital Return on invested capital runs 27.0 points above its cost of capital (6.7% WACC).
Credit BellRing Brands has 1 bond outstanding ($840M), rated B+ by the agencies and trading like B at a weighted spread of 367 bp.
Short interest Short interest is 12.7% of the free float (30 Oct 2026).
Next results Next results expected around 8 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | $2.40B | $2.40B | $2.32B | $2.00B | $1.67B |
| Revenue growth | — | +4% | +16% | +20% | — |
| Gross profit | $599M | $621M | $772M | $672M | $504M |
| EBITDA | $276M | $298M | $463M | $424M | $316M |
| Net income | $147M | $147M | $216M | $246M | $166M |
| Free cash flow | n/a | n/a | $256M | $198M | $214M |
| Capital expenditure | n/a | n/a | $4.70M | $1.80M | $1.80M |
| Total debt | $1.14B | $1.05B | $1.11B | $840M | $865M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Sector in the same market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BRBR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +43.6% | -8.6% | highest of 21 |
| 6-month return | +52.3% | +3.0% | 3rd highest of 20 |
| Distance from 52-week high | -59.3% | -41.5% | 3rd lowest of 21 |
| Revenue growth (TTM) | +3.5% | +15.7% | 9th lowest of 19 |
| Operating margin | 10.7% | -1.0% | 5th highest of 19 |
| Forward P/E | 10.6× | 17.6× | 5th cheapest of 10 |
| ROIC minus cost of capital | +27.0 pp | -9.1 pp | highest of 18 |
| EV / EBITDA | 9.5× | 7.5× | 4th most expensive of 8 |
| Net debt / EBITDA | 3.7× | 3.3× | 5th most indebted of 11 |
| Bond spread | 367 bp | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| BellRing Brands BRBR | United States | $1.59B | +52% | +4% | 11% | 10.6× | n/a | n/a |
| Sonida Senior Living SNDA | United States | $1.59B | -11% | +70% | -8% | n/a | n/a | n/a |
| Vir Biotechnology VIR | United States | $1.57B | +3% | +1,696% | -70% | n/a | n/a | n/a |
| Enovis ENOV | United States | $1.56B | +2% | +3% | 4% | 7.6× | 20.0% | -6.0% |
| Sarepta Therapeutics SRPT | United States | $1.56B | -15% | -19% | 0% | n/a | -6.8% | +32.4% |
| GeneDx WGS | United States | $1.56B | +16% | +15% | -14% | 54.2× | n/a | n/a |
| Alvotech ALVO | United States | $1.62B | +38% | -14% | 12% | 22.6× | n/a | n/a |
| Personalis PSNL | United States | $1.62B | +88% | +17% | -157% | n/a | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.62B | -13% | +26% | 15% | 7.5× | -7.6% | +33.5% |
| Butterfly Network BFLY | United States | $1.63B | +38% | +39% | -36% | n/a | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.54B | -14% | +739% | 41% | n/a | n/a | n/a |
| Precigen PGEN | United States | $1.53B | 0% | +2,388% | 21% | 7.3× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.53B | -41% | n/a | n/a | n/a | n/a | n/a |
| agilon health AGL | United States | $1.52B | +12% | +2% | -2% | 34.1× | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.52B | +54% | -64% | -5,277% | n/a | n/a | n/a |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Inspire Medical Systems INSP | United States | $1.68B | +32% | 0% | 2% | 41.3× | 28.7% | +51.2% |
| Kestra Medical Technologies KMTS | United States | $1.69B | +36% | +61% | -134% | n/a | n/a | n/a |
| DENTSPLY SIRONA XRAY | United States | $1.69B | -13% | -1% | 5% | 6.8× | 11.2% | +1.9% |
| Maze Therapeutics MAZE | United States | $1.71B | +27% | -100% | -821% | n/a | n/a | n/a |
| Astrana Health ASTH | United States | $1.47B | -24% | +35% | 3% | 17.6× | 7.4% | +35.9% |
BellRing Brands has 1 bond outstanding with $840M face value. The agencies rate it B+; its bonds trade like B. Weighted yield 8.30%, a spread of 367 bp over government bonds.